1 / 22

Eicosanoids

Eicosanoids. Overview. Eicosanoids are a large group of autocoids with potent effects on virtually every tissue in the body these agents are derived from metabolism of 20-carbon, unsaturated fatty acids ( eicosanoic acids). The eicosanoids include: the prostaglandins thromboxanes

louisedunn
Télécharger la présentation

Eicosanoids

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Eicosanoids

  2. Overview • Eicosanoidsare a large group of autocoids with potent effects on virtually every tissue in the body • these agents are derived from metabolism of 20-carbon, unsaturated fatty acids (eicosanoic acids).

  3. The eicosanoids include: • the prostaglandins • thromboxanes • leukotrienes • hydroperoxyeicosatetraenoic acids (HPETEs) • hydroxyeicosatetraenoic acids (HETEs).

  4. Biosynthesis • Arachidonic acid, the most common precursor of the eicosanoids, is formed by two pathways: • Phospholipase A2-mediated production from membrane phospholipids; this pathway is inhibited by glucocorticoids. • Phospholipase C.

  5. Eicosanoids are synthesized by two pathways: • The prostaglandin H synthase (COX, cyclooxygenase) pathwayproduces: • thromboxane • the primary prostaglandins • prostaglandin E, or PGE • prostaglandin F, or PGF • prostaglandin D, or PGD) • prostacyclin (PGI2)

  6. The lipoxygenase pathway produces: • HPETEs • HETEs • leukotrienes

  7. The eicosanoids all have short plasma half-lives (typically 0.5—5 min). • Most catabolism occurs in the lung. • Metabolites are excreted in the urine. • Thromboxane A2 (TXA2) is rapidly hydrated to the less active TXB2. • PGI2 is hydrolyzed to 6-keto-PGF1α.

  8. Various eicosanoids are synthesized throughout the body • synthesis can be very tissue specific: • PGI2 is synthesized in endothelial and vascular smooth muscle cells. • Thromboxane synthesis occurs primarily in platelets. • HPETEs, HETEs, and the leukotrienes are synthesized predominantly in mast cells, white blood cells, airway epithelium, and platelets.

  9. Actions: • Vascular smooth muscle • PGE2 and PGI2 are potent vasodilators in most vascular beds. • Thromboxaneis a potent vasoconstrictor.

  10. Inflammation • PGE2 and PGI2 cause an increase in blood flow and promote, but do not cause, edema. • HETEs (5-HETE, 12-HETE, 15-HETE) and leukotrienes cause chemotaxis of neutrophils and eosinophils.

  11. Bronchial smooth muscle • PGFs cause smooth muscle contraction. • PGEscause smooth muscle relaxation. • Leukotrienes and thromboxane are potent bronchoconstrictors and are the most likely candidates for mediating allergic bronchospasm.

  12. Uterine smooth muscle. • PGE2 and PGF2a • cause contraction of uterine smooth muscle in pregnant women. • The nonpregnant uterus has a more variable response to prostaglandins • PGF2a causes contraction • PGE2 causes relaxation.

  13. Gastrointestinal tract • PGE2 and PGF2a • increase the rate of longitudinal contraction in the gut and decrease transit time. • The leukotrienes • are potent stimulators of gastrointestinal smooth muscle. • PGE2 and PGI2 • inhibit acid and pepsinogen secretion in the stomach. • Prostaglandins • increase mucus, water, and electrolyte secretion in the stomach and the intestine.

  14. Blood • TXA2 • is a potent inducer of platelet aggregation. • PGI2 and PGE2 • inhibit platelet aggregation. • PGEs • induce erythropoiesis by stimulating the renal release of erythropoietin. • 5-HPETE • stimulates release of histamine • PGI2 and PGD • inhibit histamine release.

  15. Therapeutic uses Induction of labor at term. • Induction of labor is produced by: • infusion of PGF2a (carboprost tromethamine) [Hemabate] or • PGE2 (dinoprostone) [Prostin E].

  16. Therapeutic abortion: • Inducing abortion in the second trimester: • Infusion of carboprost tromethamine or • Administration of vaginal suppositories containing dinoprostone • inducing first-trimester abortion: • these prostaglandins are combined with mifepristone (RU486)

  17. Maintenance of ductus arteriosus • is produced by PGE1 [Prostin VR] infusion • PGE1 will maintain patency of the ductus arteriosus, which may be desirable before surgery.

  18. Treatment of peptic ulcer. • Misoprostol [Cytotec] • a methylated derivative of PGE1 • is approved for use in patients taking high doses of nonsteroidal antiinflammatory drugs (NSAIDs) to reduce gastric ulceration.

  19. Erectile dysfunction: • Alprostadil (PGE1) can be injected directly into the corpus cavernosum or administered as a transurethral suppository to cause vasodilation and enhance tumescence. injected directly into the corpus cavernosum transurethral suppository

  20. Adverse effectsof eicosanoids • local pain and irritation • bronchospasm • gastrointestinal disturbances: nausea, vomiting, cramping, and diarrhea.

More Related